BRAF-Mutated CRC
Showing 1 - 25 of 2,022
Advanced Colorectal Cancer Trial in Hangzhou (Cetuximab Dabrafenib Tislelizumab)
Not yet recruiting
- Advanced Colorectal Cancer
- Cetuximab Dabrafenib Tislelizumab
-
Hangzhou, Zhejing, ChinaZhejiang Cancer Institute & Hospital
Jul 19, 2023
Anaplastic Thyroid Cancer Trial in Leiden (dabrafenib/trametinib)
Recruiting
- Anaplastic Thyroid Cancer
-
Leiden, Zuid-Holland, NetherlandsEllen Kapiteijn
Oct 5, 2023
Associated Factors, and Clinical Outcomes of Prescribing
Completed
- BRAF v600 Mutated Metastatic Melanoma
-
East Hanover, New JerseyNovartis Pharmaceuticals
Mar 28, 2023
BRAF NP_004324.2:p.V600E, BRAF V600K Mutation Present, Thyroid Gland Anaplastic Carcinoma Trial in Duarte, Columbus (Dabrafenib,
Recruiting
- BRAF NP_004324.2:p.V600E
- +2 more
- Dabrafenib
- +2 more
-
Duarte, California
- +1 more
Jan 19, 2023
Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Malignant Tumor in the Brain, Metastatic Malignant Tumor in the CNS
Recruiting
- Clinical Stage IV Cutaneous Melanoma AJCC v8
- +3 more
- Dabrafenib
- MEK-1/MEKK-1 Inhibitor E6201
-
Scottsdale, Arizona
- +2 more
Jan 4, 2023
Stage IV Colorectal Cancer Positive for BRAF V600E Mutation, Colorectal Cancer, Colorectal Cancer Stage IV Trial in Chicago
Recruiting
- Stage IV Colorectal Cancer Positive for BRAF V600E Mutation
- +2 more
- Hydroxychloroquine in Combination With Encorafenib and Cetuximab or Panitumumab
-
Chicago, IllinoisNorthwestern University
Nov 16, 2022
Colorectal Cancer Trial in Shanghai (VIC, Bevacizumab Plus Chemotherapy)
Recruiting
- Colorectal Cancer
- VIC
- Bevacizumab Plus Chemotherapy
-
Shanghai, ChinaDepartment of General Surgery, Zhongshan Hospital, Fudan Univers
Sep 14, 2022
Triple BRAFinh/MEKinh /antiPD1 Combined Therapy in BRAF Mutated
Recruiting
- Metastatic Melanoma
-
Montpellier, FranceUhmontpellier
Aug 19, 2022
Thyroid Gland Anaplastic Carcinoma, Thyroid Gland Squamous Cell Carcinoma Trial in Houston, Salt Lake City (procedure, drug,
Recruiting
- Thyroid Gland Anaplastic Carcinoma
- Thyroid Gland Squamous Cell Carcinoma
- Conventional Surgery
- +5 more
-
Stanford, California
- +5 more
Jan 26, 2023
Non-small-cell Lung Cancer Trial (HL-085+Vemurafenib)
Not yet recruiting
- Non-small-cell Lung Cancer
- (no location specified)
Jun 8, 2023
BRAF V600-mutated Lung Carcinoma Treated With Combination of
Completed
- Non Small Cell Lung Cancer
- BRAF V600 Mutation
-
Créteil, France
- +1 more
Jun 29, 2022
Colon Adenocarcinoma, Microsatellite Stable Colon Carcinoma, Stage IIB Colon Cancer AJCC v8 Trial (drug, biological, procedure,
Not yet recruiting
- Colon Adenocarcinoma
- +4 more
- Encorafenib
- +5 more
- (no location specified)
Jan 24, 2023
Melanoma (Skin) Trial in Dijon, Thionville, Vandœuvre-lès-Nancy (Blood sampling)
Active, not recruiting
- Melanoma (Skin)
- Blood sampling
-
Dijon, France
- +3 more
Mar 29, 2022
BRAF Inhibitor Encorafenib And Cetuximab Real Life Investigation
Recruiting
- Metastatic Colorectal Carcinoma
-
Aschaffenburg, Germany
- +11 more
Dec 13, 2020
Melanoma Trial in Tampa (XL888, Vemurafenib)
Active, not recruiting
- Melanoma
-
Tampa, FloridaH. Lee Moffitt Cancer Center and Research Institute
Aug 18, 2022
Disease or R Group Histiocytoses Trial in Paris (Cobimetinib, Placebo oral tablet)
Active, not recruiting
- Disease or R Group Histiocytoses
- Cobimetinib
- Placebo oral tablet
-
Paris, FranceService de Médecine interne - La Pitié Salpêtrière
Mar 21, 2022
BRAF V600E Unresectable or Metastatic Melanoma, BRAF V600E Metastatic NSCLC, Melanoma Trial in Guangzhou (Encorafenib)
Completed
- BRAF V600E Unresectable or Metastatic Melanoma
- +2 more
-
Guangzhou, Guangdong, ChinaSun Yat-sen University Cancer Center
Jun 9, 2022
Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Melanoma Trial in United States (Dabrafenib Mesylate, Tazemetostat
Recruiting
- Clinical Stage IV Cutaneous Melanoma AJCC v8
- Metastatic Melanoma
- Dabrafenib Mesylate
- +2 more
-
Atlanta, Georgia
- +6 more
Nov 30, 2022
Metastatic Colorectal Cancer Trial in Munich (Bevacizumab, Irinotecan, Folinic acid)
Active, not recruiting
- Metastatic Colorectal Cancer
- Bevacizumab
- +5 more
-
Munich, GermanyKlinikum der Universitaet Muenchen
Dec 2, 2021
Malignant Melanoma, Brain Metastases Trial in Tucson (E6201, E6201 plus dabrafenib)
Terminated
- Malignant Melanoma
- Brain Metastases
- E6201
- E6201 plus dabrafenib
-
Tucson, ArizonaUniversity of Arizona Cancer Center
Mar 5, 2022
Melanoma Trial in Pierre-Bénite (Skin biopsy)
Recruiting
- Melanoma
- Skin biopsy
-
Pierre-Bénite, FranceService de Dermatologie, Centre hospitalier Lyon Sud, HCL
Jul 5, 2021
Colorectal Cancer Trial in Hangzhou (Surufatinib, Toripalimab, chemo)
Recruiting
- Colorectal Cancer
- Surufatinib
- +2 more
-
Hangzhou, Zhejiang, ChinaFirst affiliated hospital, Zhejiang University
Feb 26, 2022